Improving results with greater precision

Article

Experiences with PASCAL sub-threshold laser treatments for DME

Fortunately, advances in laser therapy have yielded refinements in pulse duration, lesion intensity and several other parameters, improving overall quality of treatment. A recent application furthering physician control over these factors is the Endpoint Management software available for the PASCAL Photocoagulator (Topcon Medical Laser Systems, Santa Clara, California, USA).

Development of treatment protocols

The goal of focal laser treatment for DME should be to combine safety with efficacy. In this case, that means a resolution of - or, at least, a significant reduction of - macular oedema. Hopefully, this will facilitate improved or preserved vision. The idea that visible lesions are not necessary for effective treatment has been reinforced by the recent success of micropulse lasers.3 However, one distinct disadvantage of micropulse is its difficulty and complexity in setting laser dosimetry. A key advantage of Endpoint Management is its Landmark feature, which delivers laser application at the visible, titrated dose.

The goal of sub-threshold laser treatment is to achieve the best results with reduced energy, thereby reducing unintended effects from thermal reaction. Endpoint Management first titrates to a comfortable visible endpoint and then uses algorithms to modulate power and duration, enabling control over treatment endpoints.

New options

I then apply my laser treatment pattern, typically using 2x2 and arc grid patterns. I can add a grid with uniform intensity or vary the grid so that landmarks use a higher amount of energy than central points. In this instance, endpoints would deliver a reduced amount of energy as set by the endpoint percentage. These points would use just enough energy to stimulate the retina into pumping out accumulated fluid, but not enough to cause visible whitening of the RPE and actual thermal burn. Here, greater physician control yields a more precise - and potentially efficacious - treatment.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.